Article Details

Here's Why Immunovant (IMVT) Outperformed in Q3 - Yahoo Finance

Retrieved on: 2023-12-01 18:52:43

Tags for this article:

Click the tags to see associated articles and topics

Here's Why Immunovant (IMVT) Outperformed in Q3 - Yahoo Finance. View article details on hiswai:

Excerpt

... monoclonal antibodies for the treatment of autoimmune diseases. The company's lead asset, IMVT-1402 is a next-generation antibody drug that has ...

Article found on: finance.yahoo.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo